Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Siemens Medical Solutions

Feb 2007
Siemens Medical Solutions of Hoffman Estates, Ill., has received clearance from the FDA to begin clinical trials on an imaging biomarker for Alzheimer’s diagnosis. The company will conduct the Phase I safety study in conjunction with the University of California, Los Angeles, to determine the biomarker’s effectiveness in detecting amyloid plaques and tangles in patients’ brains.

Siemens also has received FDA 510(k) clearance for the first six of many planned dual-energy applications for its Somatom Definition dual-source computed tomography system. The applications will allow the system — whose temporal resolution enables it to capture images independent of heart rate and without beta blockers — to perform functions such as CT angiography.

amyloid plaquesBiophotonicsFDANews & FeaturesSiemens Medical Solutions

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x Subscribe to BioPhotonics magazine - FREE!
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.